---
reference_id: "PMID:37121243"
title: Haemochromatosis.
authors:
- Adams PC
- Jeffrey G
- Ryan J
journal: Lancet
year: '2023'
doi: 10.1016/S0140-6736(23)00287-8
content_type: abstract_only
---

# Haemochromatosis.
**Authors:** Adams PC, Jeffrey G, Ryan J
**Journal:** Lancet (2023)
**DOI:** [10.1016/S0140-6736(23)00287-8](https://doi.org/10.1016/S0140-6736(23)00287-8)

## Content

1. Lancet. 2023 May 27;401(10390):1811-1821. doi: 10.1016/S0140-6736(23)00287-8. 
Epub 2023 Apr 27.

Haemochromatosis.

Adams PC(1), Jeffrey G(2), Ryan J(3).

Author information:
(1)Department of Medicine, Schulich School of Medicine & Dentistry, Western 
University, London, ON, Canada. Electronic address: padams@uwo.ca.
(2)Medical School, University of Western Australia, Perth, WA, Australia.
(3)Royal College of Surgeons of Ireland, Dublin, Ireland.

Comment in
    Lancet. 2023 Aug 26;402(10403):690-691. doi: 10.1016/S0140-6736(23)01506-4.
    Lancet. 2023 Aug 26;402(10403):691-692. doi: 10.1016/S0140-6736(23)01507-6.

Haemochromatosis is one of the most common genetic diseases affecting patients 
of northern European ancestry. It is overdiagnosed in patients without iron 
overload and is underdiagnosed in many patients. Early diagnosis by genetic 
testing and therapy by periodic phlebotomy can prevent the most serious 
complications, which include liver cirrhosis, liver cancer, and death. This 
Seminar includes an update on the origins of haemochromatosis; and an overview 
pathophysiology, genetics, natural history, signs and symptoms, differential 
diagnoses, treatment with phlebotomy, outcomes, and future directions.

Copyright Â© 2023 Elsevier Ltd. All rights reserved.

DOI: 10.1016/S0140-6736(23)00287-8
PMID: 37121243 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of interests PCA has been an advisor 
to Sanofi and Imara. JR has consulted for Bond Biosciences, Pfizer, Gilead, 
Kyowa Kirin, and Falk. GJ declares no competing interests.